A jury upheld Merck’s claim that Gilead Sciences violated patent protections on hepatitis C treatments Sovaldi and Harvoni and ordered Gilead to pay $2.54 billion in royalties. Gilead spokeswoman Michele Rest said the company would appeal the federal court decision.